Kif15-IN-2 is a novel and potent inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.

Physicochemical Properties

Molecular Formula	C₂₀H₂₀N₆O₄S
Molecular Weight	440.4756
Exact Mass	440.126
CAS #	672926-33-9
PubChem CID	60076305
Appearance	White to off-white solid powder
Density	1.4±0.1 g/cm3
Index of Refraction	1.639
LogP	1.57
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Heavy Atom Count	31
Complexity	724
Defined Atom Stereocenter Count	1
SMILES	CC1=C(SC(=N1)NC(=O)[C@H](C(C)C)N2C(=O)C3=CC=CC=C3NC2=O)C4=NN=C(O4)C
InChi Key	OHVKUJISCPKSER-AWEZNQCLSA-N
InChi Code	InChI=1S/C20H20N6O4S/c1-9(2)14(26-18(28)12-7-5-6-8-13(12)22-20(26)29)16(27)23-19-21-10(3)15(31-19)17-25-24-11(4)30-17/h5-9,14H,1-4H3,(H,22,29)(H,21,23,27)/t14-/m0/s1
Chemical Name	(S)-2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-3-methyl-N-(4-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)thiazol-2-yl)butanamide
Synonyms	Kif15-IN-2 Kif15 IN 2 Kif15 IN-2 Kif15-IN 2
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Kif15-IN-2 (Compound 14) is an inhibitor of the mitotic kinesin Hs Kif15 and has potential efficacy against cell proliferative illnesses, such as cancer, hyperplasia, restenosis, cardiac hypertrophy, immunological disorders and inflammation [1].
References	[1]. Quinazolinedione derivatives useful for treating cellular proliferative disorders and disorders associated with Kif15 kinesin activity are described. US 20040053948 A1.

Solubility Data

Solubility (In Vitro)

DMSO : ~20 mg/mL (~45.41 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2703 mL	11.3513 mL	22.7025 mL
	5 mM	0.4541 mL	2.2703 mL	4.5405 mL
	10 mM	0.2270 mL	1.1351 mL	2.2703 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.